At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 23 enrolled
Drug / intervention
PF-04449913drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF 04449913, AN ORAL HEDGEHOG INHIBITOR, ADMINISTERED AS SINGLE AGENT IN SELECT SOLID TUMORS
In Brief
A Phase 1 clinical trial evaluating PF-04449913 for Solid Tumors. Completed, enrolled 23 participants across 9 sites.
Detailed Summary
This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2011
Enrollment StartMay 2011
Primary CompletionMay 2012
Study CompletionDec 2012
TodayJul 2026
First PostedJan 31, 2011
Enrollment StartMay 11, 2011
Primary CompletionMay 10, 2012
Study CompletionDec 28, 2012
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 15.4 years ago
Interventions
PF-04449913drug
Escalating dose of PF-04449913 administered as tablets PO QD in 28-day cycles